Cargando…
Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination
The renin–angiotensin–aldosterone system (RAAS), an important regulator of blood pressure and mediator of hypertension-related complications, is a prime target for cardiovascular drug therapy. Angiotensin-converting enzyme inhibitors (ACEIs) were the first drugs to be used to block the RAAS. Angiote...
Autores principales: | Cagnoni, Francesca, Njwe, Christian Achiri Ngu, Zaninelli, Augusto, Ricci, Alessandra Rossi, Daffra, Diletta, D’Ospina, Antonio, Preti, Paola, Destro, Maurizio |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922316/ https://www.ncbi.nlm.nih.gov/pubmed/20730071 |
Ejemplares similares
-
Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update
por: Destro, Maurizio, et al.
Publicado: (2010) -
Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS)
por: Natarajan, Aruna, et al.
Publicado: (2008) -
Antifibrotic Roles of RAAS Blockers: Update
por: Zhang, Ying-Ying, et al.
Publicado: (2019) -
Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy
por: Ghazi, Lama, et al.
Publicado: (2017) -
Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes
por: Gnudi, Luigi, et al.
Publicado: (2010)